脑胶质瘤EGFR、KRAS和Ki67蛋白的表达及临床意义

Clinical significance of EGFR, KRAS and Ki67 protein expressions in gliomas

关键词:  胶质瘤  EGFR  KRAS  Ki67

Key words:  Gliomas  EGFR  KRAS  Ki67

摘要:

目的　研究胶质瘤表皮生长因子受体（epidermal growth factor receptor, EGFR）、原癌基因KRAS蛋白以及与细胞增殖有关的核抗原Ki67蛋白的表达情况，为胶质瘤的靶向TKI治疗提供依据。方法　选取大连医科大学附属第二医院神经外科2001-2010年间手术切除的胶质瘤标本81例，按照患者临床病理特点及肿瘤WHO(World Health Organization)分级予以分组，用免疫组织化学方法检测组织的EGFR、KRAS和Ki67在胶质瘤中的表达情况，通过统计学分析这些蛋白表达与临床病理参数之间的关系及这些蛋白表达之间的相关性。结果　EGFR蛋白表达阳性率在年龄≤42岁与>42岁患者组分别为57.5%与80.5%，两者差异显著（P<0.05）；在低级别与高级别患者组分别为56.3%与77.6%，两者差异显著（P<0.05）。KRAS蛋白表达阳性率与患者性别，年龄及肿瘤分级无明显关系（P>0.05）。Ki67蛋白表达阳性率在低级别与高级别患者组间表达的差异具有显著性意义（P=0.001）。胶质瘤EGFR蛋白表达与KRAS及Ki67蛋白表达亦无显著相关关系（P>0.05）。胶质瘤Ki67蛋白表达与KRAS蛋白表达亦无显著相关关系（P>0.05）。结论　胶质瘤EGFR、KRAS蛋白的表达为相互独立的分子事件的发现提示胶质瘤发病机制的多样性；EGFR， Ki67蛋白的表达可用于辅助判定肿瘤的病理级别。

Abstract:

Objective To study the clinical significance of EGFR, KRAS and Ki67 expressions in glioma. Methods The postoperative glioma tissues were collected and divided into groups according to the clinicopathological agents and the classification of the WHO(World Health Organization). EGFR, KRAS and Ki67 expressions in glioma were detected by immunohistochemistry. Results EGFR protein expression frequency were 57.5% and 80.5% in the below and over 42-year-old age groups (P<0.05); 56.3% and 77.6% in the low grade and high grade groups (P<0.05). KRAS protein expression was not correlated to the genders, ages of patients and the grades of glioma (P>0.05). Ki67 protein expression frequency were 31.3% and 69.4% in the low grade and high grade groups (P<0.05). EGFR expression was not correlated to the expression of KRAS or Ki67(P>0.05). Ki67 expression was not correlated to KRAS expression (P>0.05). Conclusion In gliomas, EGFR and KRAS expressions were independent, which would suggest that many molecular mechanisms involved in the carcinogenesis and development of gliomas.